Thank you for donating!

You can donate using the following services.


  1. 12.09.19

    CTD Holdings to Present at 2019 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

    CTD is also a proud sponsor of the NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Diseases, for the 4th year running...

    Read more
  2. 12.09.19

    ASMD Research Study Opportunity

    Evidera, a research group working on behalf of Sanofi Genzyme, is conducting a research study to understand the symptoms and impact experienced by carers of those affected by ASMD Niemann-Pick disease types B, or A/B...

    Read more
  3. 30.08.19


    Copenhagen, Denmark, August 28, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights...

    Read more
  4. 11.08.19

    Questions from the NPC community regarding the suspension of VTS-270 301 in UK and France (Mallinckrodt)

    Mallinckrodt answer questions from the NPC community regarding the suspension of VTS-270 301 in UK and France...

    Read more
  5. 02.08.19

    Mallinckrodt: official statement regarding the Study 301 suspension

    The following article features a letter regarding the Study 301 Suspension from Sheila Talafous, Director of Advocacy Relations at Mallinckrodt Pharmaceuticals...

    Read more